GILD Stock UPDATES Gilead Sciences (GILD) 109.43 09/03/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 3, 2014 at 9:07 PM

Gilead Sciences (GILD) 109.43 $GILD

Roche's Cobas 6800/8800 Testing Systems Launched - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 12 mins ago
Roche (RHHBY) announced that its cobas 6800/8800 systems -- two integrated and fully automated molecular testing systems for blood and plasma donor screening are commercially available in markets which accept the CE mark.

Infinity Pharma (INFI) Shares Skyrocket on Cancer Drug Partnership - Stocks in the News
Zacks Research Staff - Zacks Investment Research - 2 hrs 19 mins ago
Shares of Infinity Pharma (INFI) are up more than 40 percent thanks to news of a partnership with AbbVie for a new cancer drug.

Sanofi Reports Positive Phase III Data on Dengue Vaccine - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 27 mins ago
Sanofi (SNY) announced that a phase III efficacy study on its dengue vaccine candidate has met the primary endpoint.

New Managers Revive Thrivent Large Cap Growth Fund
at Investor's Business Daily - 2 hrs 39 mins ago
Thrivent Large Cap Growth is a reminder of how new managers can herald a change in a mutual fund's fortune. David Francis and Darren Bagwell, now co-managers, took the helm of the $521 million portfolio on Oct. 1, 2011. In the three years prior to...

Three Stocks Top-Performing Funds Like: Facebook Baidu Gilead
at Investor's Business Daily - 2 hrs 39 mins ago
The new buys list of top-performing funds the past three months showed some heavy buying of top-rated stocks. The nation's leading funds have been stocking up on medical issues, which fared well as the market resumed its uptrend in August. Large...

Final Glance: Biotechnology companies
AP - 2 hrs 53 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:

Arena Pharmaceuticals' APD811 Gets Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 4:20PM CDT
Arena Pharmaceuticals, Inc. announced that its pulmonary arterial hypertensioncandidate APD811 has received orphan drug status from the FDA.

Bayer Discloses Encouraging Data on Anticoagulant Xarelto - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 4:10PM CDT
Bayer (BAYRY) announced encouraging results from the X-VeRT study on Xarelto.

Gilead Sciences to Present at Two Upcoming Investor Conferences in September
Business Wire - Wed Sep 03, 4:00PM CDT
--- 2014 Morgan Stanley Global Healthcare Conference -

Midday Glance: Biotechnology companies
AP - Wed Sep 03, 12:34PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:

Infinity Pharma Joins AbbVie On Blood Cancer Drug
at Investor's Business Daily - Wed Sep 03, 12:20PM CDT
Development-stage biotech Infinity Pharmaceuticals (INFI) landed a key deal to develop its blood cancer drug duvelisib in partnership with big pharma AbbVie (ABBV), sending Infinity stock up 46% to a six-month high near 16 on the stock market today....

Bristol-Myers Returns Clazakizumab Rights, Alder Sinks - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 10:02AM CDT
Bristol-Myers' (BMY) decision to opt out of the development process of clazakizumab caused the shares of Alder (ALDR) to plummet significantly.

Early Glance: Biotechnology companies
AP - Wed Sep 03, 9:28AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:

Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 03, 9:10AM CDT
A favorable court ruling for United Therapeutics, positive late-stage data on a testosterone replacement treatment and the filing of the first BLA for a PCSK9 inhibitor were last week's highlights.

Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay
PR Newswire - Wed Sep 03, 8:05AM CDT
The US markets on Tuesday, September 02, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 17,067.56, down 0.18% and the NASDAQ Composite closed at 4,598.19, up 0.39%. The S&P 500 finished the session 0.05% lower at 2,002.28. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 737.75, up 0.02%, with the index gaining 6.88% in the previous three months. Investor-Edge has initiated coverage on the following equities: Galena Biopharma Inc. (NASDAQ: GALE), Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), Orexigen Therapeutics Inc. (NASDAQ: OREX), and IsoRay Inc. (NYSE MKT: ISR). Free research on these five companies can be accessed at:

Alder Biopharmaceuticals Slumps: ALDR Tanks 13.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 7:51AM CDT
Alder Biopharmaceuticals has seen negative earnings estimate revisions for the current year along with a significant decline in its share price for the past 24 hours

Infinity Pharma Snags Abbvie for Blood Cancer Drug Partnership
at The Street - Wed Sep 03, 5:57AM CDT
Infinity and Abbvie will jointly develop and market duvelisib.

Bristol-Myers/Pfizer's Eliquis Encourages in VTE Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:50PM CDT
Encouraging results on Bristol-Myers /Pfizer's (BMY/PFE) Eliquis was presented from an analysis of a phase III study.

AstraZeneca Reports Data on Brilinta from ATLANTIC Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:40PM CDT
AstraZeneca (AZN) announced data from the phase IV ATLANTIC study on Brilinta.

Bayer/Johnson & Johnson to Expand Xarelto Label Further - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:30PM CDT
Bayer (BAYRY) and Johnson & Johnson (JNJ) announced that they will be evaluating Xarelto in three new indications.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ceva's Wireless IP Dominance Amid AI Device Surge

Keeping the Wireless IP Crown Against All Odds Look, I've seen dominance play out in the markets over the years, but Ceva’s stranglehold on the wireless interface IP market is something fierce. They've got a whopping 68% market share, and folks, that’s 12 times their closest competitor. Talk about leaving the competition eating dust! For a field growing at a solid...

Watches of Switzerland Dazzles with Holiday Campaign

Swiss Timepieces Take Center Stage Ever feel like there's a certain art to gift-giving? Apparently, The Watches of Switzerland Group thinks so, and they're not holding back in showing us how it's done with their new 'Brilliantly Given' campaign. They’re taking a classic approach by spotlighting luxury timepieces and fine jewelry just in time for the holiday...

Aosom Unveils Its Boldest Black Friday Extravaganza

Black Friday Heat Kicks Off Early at Aosom All the seasoned shoppers out there smell a deal from a mile away, and Aosom isn't taking any chances by launching their Black Friday bash smack dab on November 2nd. This isn’t just any sale, it’s shaping up to be their most gigantic festival of discounts yet. Across Europe and North America, folks are rubbing their hands...

Zensar Sees Solid Revenue Growth in Q2FY27

Zensar's Q2 Performance: Growth Amid Shifting Sands Is Zensar Technologies quietly carving a spot for itself in the cutthroat tech marketplace, or are we just seeing a temporary glimmer during a complex market scenario? With a constant currency growth rate of 4.1% in Q2FY27, Zensar sure seems to have gotten something right. But does this mean they’ve got the long-term...

German Court Backs Usmanov in Legal Standoff with EU

Usmanov Scores a Win in German Courts The courtroom dramas play out yet again, and this time the spotlight's on Alisher Usmanov versus the European Union Council. It's a scene rich in bureaucratic fireworks, where Germany's Federal Court of Justice shined a beam of clarity amidst all that legal fog. They call it a 'landmark ruling'—a voice of reason brushing aside the...

Envision's 800V DC System Cuts the Powercake First

Envision Hits a Milestone in AI Power Dynamics You ever feel like the future is knocking on your door, but you've still got your headphones on? Well, Envision just kicked the door open with the world's first commercial deployment of an integrated 800-volt direct current (800V DC) power system in a large-scale AI data center. This technological marvel is now up and running...

Atrium's Heart Therapies: ATR 1072's Promising Data

Atrium Therapeutics Strikes a Chord with New Data Tuning into the heartbeats of breakthrough developments, Atrium Therapeutics dropped some fresh, nonclinical insights about their latest contender, ATR 1072. This wasn't just any ordinary announcement; it's like when the market hears whispers of a Fed rate adjustment. The venue? The American Heart Association's 2026...

Why Renters Insurance is a Must for Tenants

Diving Into Renters Insurance: What You Need to Know Renters insurance isn't just another unnecessary add-on; it's practically a necessity if you're renting. Joseph Puckett, of Golseth and Puckett Agency: Allstate Insurance, gives us the lowdown on the essential protection renters need but often overlook. The Myth and the Reality Ah, the age-old misconception—many...

Immunic's November Moves: Conferences and Clinical Trials

Immunic Taps Into November Conferences Every now and then, you catch a company that's not just spinning its wheels but making some potentially big waves in their field. This time, it's Immunic, Inc. (Nasdaq: IMUX), stepping into the spotlight. They're strutting their stuff at several investor conferences this November, starting with Boston and New York, then hopping over...

Lectric Rolls Out Limited-Edition XP4 Ebike Upgrades

Pedaling into a New Era of eBikes When the top contender in the American eBike world rolls out something new, you'd better believe it's worth a look. Lectric eBikes has just unwrapped three limited-edition versions of their beloved XP4, revealing a fresh take on a ride already admired by thousands. Let's dig into this new release. What's New with the XP4 This ain't just a...